Fig. 1. Da Vinci robot 1985
First surgical robot utilization (Neurosurgery) 1989 First urologic robot (Probot) 1993 First commercially available robot approved by the FDA (AESOP) 1998
Zeus system commercially available 2000
First robotic radical prostatectomy 2001
FDA clearance for Da Vinci system 2003
The Zeus system and Intuitive Surgical fusion Table 1 . Robotic surgery timeline
Prostatectomy
Robotic-assisted laparoscopic radical prostatectomy (RARP) was first reported in 2000 (Abbou et al., 2000) . Since then the number of patients undergoing RARP for prostate cancer has steadily increased. Early comparisons between radical retropubic prostatectomy (RRP) and RARP show encouraging results. Menon et al. in a prospective nonrandomized study, compared results of 30 consecutive patients undergoing (RRP) and 30 initial patients undergoing (RARP) . Estimated blood loss (EBL), blood transfusions, pain score, hospital stay, and mean duration of postoperative catheterization were improved in the RARP group. However, the mean operating time increased for RARP (Menon et al. 2002) . In a recent review, Ficcara et al. found that the mean OR time for RARP ranged between 127 and 288 minutes, corroborating a longer operative time with robotics versus open. Nevertheless, transfusion rates and hospital stay were lower with RARP then open RRP. In addition there were comparable complication rates between the RARP and open RRP patients (Ficarra et al., 2009) .
Positive surgical margins are a surrogate for oncological outcomes reported for RARP. A significant advantage in positive margin rates was demonstrated for RALP over RRP. This same difference amongst the robotic and open groups does not exist when comparing laparoscopic radical prostatectomy (LRP). The positive surgical margin rates ranged from 11% to 37% after RRP, from 11% to 30% after LRP, and from 9.6% to 26% after RALP (Ficarra et al., 2009) . Recently, survival outcomes have been reported after RARP. Barocas et al. compared 491 open RRP with 1,413 patients undergoing RARP, over a median follow-up of 10 months (Barocas et al., 2010) . Robotic group had lower pathological stage (80.5% pT2 vs 69.6% pT2, p <0.01). The 3-year biochemical recurrence-free survival rate was similar between the 2 groups, even after adjusting for pathological stage, grade and margin status. More recently, comparisons of 522 consecutive RARP were matched to patients who underwent LRP and RRP evaluating oncological outcomes (Magheli et al., 2011) . Positive surgical margin rates were higher in the robotic group (19%), compared to LRP (13%) and RRP (14%). This difference was not significant for pT2 disease. The mean follow-up was 2.5, 1.4 and 1.3 years for RRP, LRP and RARP respectively, with no statistically significant difference in biochemical-free survival between groups. Erectile function and continence are major outcomes evaluated after prostatectomy. In a matched cohort, comparing 294 RARP for clinically localized prostate cancer with 588 RRP, showed no difference in continence between the 2 approaches at the 1-year follow-up (Krambeck et al. 2009 ). Furthermore, Roco et al showed 1year continence rates of 97% vs 88% after RARP and RRP, respectively (P = 0.014). The 1 year overall potency recovery rate was 61% vs 41%, after RARP and RRP, respectively (P = 0.003). Overall, RRP seems to be a faster procedure. However, EBL, hospitalization time, and functional outcomes were superior with RARP. Early oncological outcome seemed to be equivalent in the two groups (Rocco et al., 2009 ). The drawback of RARP is the cost related to purchasing and maintaining the instruments of the robotic system. Bolenz et al. compared the cost of 262 RALP, 220 LRP, and 161 RRP performed at the same institution. The direct cost was higher for the robotic approach than laparoscopic or open. The median direct cost was US$ 6752, US$ 5687, and US$ 4437 for RALP, LRP, and RRP respectively. The most important difference was due to surgical supply and operating room cost (Bolenz et al., 2010) . However, the surgical volume may reduce this difference. Scales et al. showed that the cost of RALP is volume dependent, and cost equivalence is achievable with RRP at a surgical volume of 10 cases weekly (Scales et al., 2005) . Even the cost of robotic surgery is a difficult question to assess; the costeffectiveness of robotics will probably continue to improve with time (Wilson & Torrey, 2011) . The available data demonstrates improvements in blood loss, hospital stay, and pain control with RALP. However the lack of long term cancer specific mortality limits robust oncological comparisons of RARP to RRP.
Radical nephrectomy
Robotic radical and simple nephrectomy is a feasible and safe procedure. A comparison of 46 laparoscopic nephrectomies, 20 hand-assisted laparoscopic nephrectomy, and 13 robotic nephrectomies showed no significant advantage of robotics over traditional laparoscopy or hand-assisted approaches. However, cost analysis illustrated far more cost with robotics among the three groups (Boger et al., 2010) .
Platforms where robotics may be applied to radical nephrectomies are complex tumors with caval thrombosis. Abaza reported five patients with a renal tumor and inferior vena cava (IVC) thrombus who underwent robotic nephrectomy. The robotic system allowed for venotomy into the vena cava with suture of the defect and no complications. (Abaza, 2011) Robotic-assisted nephrectomy was also applied for live kidney donor. A series of 35 first cases was reported with a mean warm ischemia time of 5.9 minutes. (Louis et al., 2009 ). However, the cost of the robotic approach may limit its applicability for radical nephrectomies except in complex renal cases with caval thromsis.
Partial nephrectomy
The da Vinci Surgical System provides advantages during robotic partial nephrectomy (RPN) such as 3-D vision, articulating instruments, scaling of movement, tremor filtration, fourth robotic arm assistance, and the TilePro™ software (Intuitive surgical, Sunnyvale, CA), a live intra-operative ultrasound platform. All these tools are helpful during partial nephrectomy and may overcome the technical challenges of laparoscopic partial nephrectomy (LPN). Since the first report by Gettman et al. showing the feasibility of robotic assisted partial nephrectomy (RPN) (Gettman et al., 2004) , a steadily increasing number of series have been reported.
Forty consecutive RPN and 62 LPN were retrospectively compared in a study by wang and colleagues showing no significant difference in EBL, collecting system repair (56% for each group), or positive margin rate (1 case in each group). Furthermore, the mean operative time, warm ischemia time (19 vs 25 minutes, for RPN and LPN respectively), and length of stay decreased significantly in the robotic group (Wang & Bhayani, 2009 (Haber et al., 2010a) . The safety and effectiveness of RPN regarding functional and oncologic outcomes were evaluated in a multi-institutional review with 183 patients who underwent RPN (Benway et al., 2010) . The means of peri-operative demographics and outcomes were analyzed illustrating a tumor size 2.87 cm, total operative time 210 min, warm ischemic time 23.9 min, and EBL of 131.5 ml. Sixty-nine percent of excised tumors were malignant, of which 2.7% had positive surgical margins. The incidence of major complications was 8.2%. At up to 26 months follow-up, there have been no recurrences and no significant change in renal function. Additionally, indications for RPN have significantly expanded to include RPN for complex renal tumors (Rogers et al., 2008a; White et al., 2011) . White et al. reviewed 67 patients who underwent RPN for a moderately or highly complex renal mass according to the R.E.N.A.L. nephrometry score (≥7). The median tumor size was 3.7 cm, median operative time was 180 minutes, median EBL was 200 mL, and the warm ischemia time was 19.0 minutes (range 15-26). After a mean follow-up of 10 months, no recurrences had occurred indicating that RPN is a safe and feasible option for highly complex renal masses (White et al., 2011) . RPN seems to be as an effective and safe alternative to LPN. Surgical technique for RPN has improved and indications have been expanded to more challenging tumors. Currently available comparative studies are retrospective and with a limited follow-up. Future trials are expected to confirm encouraging findings from early reported series.
Adrenalectomy
Robotic-assisted adrenalectomy (RAA) was first reported in 1999 and 2001 using the Aesop (Hubens et al., 1999) and Da Vinci systems, respectively (Horgan & Vanuno, 2001) . Since then, the few studies published were about RAA using Da Vinci system. Brunaud et al. prospectively evaluated 100 consecutive patients who underwent RAA. The mean operative time was 95 minutes with a conversion rate 5%. Complication and mortality rates were 10% and 0%, respectively. The mean operative time decreased by 1 minute every 10 cases. Operative time improved more for junior surgeons than for senior surgeons after the first 50 cases. Surgeon's experience, first assistant level and tumor size were independent predictors of operative time. The robotic procedure was 2.3 times more costly than laparoscopic adrenalectomy (Brunaud et al., 2008a) . The same authors, compared prospectivly perioperative data of 50 patients who underwent RAA with 59 patients who underwent laparoscopic adrenalectomy (LA). RAA was associated with lower blood loss but longer operative times. However, the difference in operative time was not significant after the learning curve of 20 cases. Operative time increased, only in the LA group for obese patients (body mass index >30 kg/m2) and patients with large tumors (>55mm). Length of hospital stay, complication and conversion rates were equivalent in the groups (Brunaud et al., 2008b) .
Recently, Giulianotti et al. examined 42 patients who underwent RAA by a single surgeon. Median hospital stay was 4 days with postoperative complication rate of 2.4% and mortality rate of 2.4% (Giulianotti et al., 2011) .
Suggestions have been made that robot assistance may be beneficial for obese patients with large tumors (Brunaud et al., 2008a; Giulianotti et al., 2011) , as well as for surgeons with limited laparoscopic experience. Regardless of its feasibility, Prospective studies must focus on potential improve in learning curve with robotic utilization along with a cost analysis evaluating RAA compared to current standards. (Brunaud et al., 2008a) 
Pyeloplasty
The first clinical experience of robot-assisted pyeloplasty (RAP) was reported in 2002 (Gettman et al., 2002a (Cestari et al, 2010) . Studies of RAP demonstrate feasibility, efficacy and safety. However, the cost of robotic surgery continues to limit the widespread application of this platform.
Cystectomy
Radical cystectomy with pelvic lymphadectomy (PLND) remains the gold-standard treatment for patients with muscle-invasive blader cancer. However, morbidity related to open radical cystectomy (ORC) presents a real challenge. Thus, robotic-assisted radical cystectomy (RRC) represents a potentiel alltenative to the open approach. Similar to other robotic procedures, the potential advantages of RRC over ORC are decrease in blood loss, pain, and hospital stay. On the other hand, the oncologic outcomes of the RRC remain largely unknown. In a series of 100 consecutive patients who underwent RRC for clinically localized bladder cancer, the mean operative time was 4.6 hours and an EBL 271 ml. Mean hospital stay was 4.9 days with 36 patients experiencing postoperative complications; 8% major complications. Urinary diversion included, ileal conduits 61 % of the time . Kauffman et al. presented results of 85 consecutive patients treated with RRC for bladder cancer. The median age was 73.5 years with high proportion of patients having comorbidities (46% of ASA class ≥3). Extended pelvic lymphadenectomy was performed in almost all patients (98%). Extravesical disease was found in 36.5% cases and positive surgical margins were present in 6% of patients. At a mean follow-up of 18 months, 20 (24%) patients had presented recurrence; three of them (4%) only had a local recurrence. The overall survival and disease-specific survival rates for the cohort at 2 years were 79% and 85%, respectively. Extravesical disease, positive lymph node, and lymphovascular invasion were associated with worse prognosis (Kauffman et al., 2011) . Even with the encouraging results of this study, comparative analysis and long term outcomes are still needed. Josephson et al., in his report of 58 RRC, found different results, with a overall survival rate of 54% and disease specific survival rates of 76% at 2-year (Josephson et al., 2010) . However, stratification of survival outcomes by patholoical stage was not reported, making comparasions with other studies futile.
In an others series of 100 patients with a mean follow up of 21 months, 15 patients had disease recurrence and 6 died of bladder cancer . Comparisons between open and robotic cystectomy are lacking because of the heterogenity in disease burden and patient selection.
In a multi-institutional study, of the 527 patients who underwent RRC, 437 (82.9%) had a lymphadenectomy. Surgeons experience on the robot influenced whether a lymphadenectomy was performed (Hellenthal, 2010a) . In the same data base, the Positive surgical margin was 6.5% (Hellenthal, 2010b) . In a study of 100 consecutive patients with RRC, no positive margin was found . However in this series only 13% cases were pT3/T4 at the final pathology, which may explain this result. RRC offers the potential for improving peri-operative outcomes with the advantages of minimally invasive surgery. It may offer shorter hospital stay, decrease blood loss and pain, and offer a smaller incision, with equal complication rates and oncological outcomes to the current gold standard, ORC. Future studies with longer follow up are essential to have robust data on the comparability of RRC to ORC
Robotic laparoendoscopic single-site surgery and natural orifice translumenal endoscopic surgery: Current status
Laparoendoscopic single-site surgery (LESS) ( Figure. 2) and natural orifice translumenal endoscopic surgery (NOTES) exploit the use of a single incision or natural entry points into the body cavity. A trend towards scareless surgery with the advantages of laparoscopy has fueled the development of a novel surgical technique, LESS and NOTES. The first laparoscopic transvaginal nephrectomy (NOTES) in a porcine model was described in 2002, introducing another achievable surgical approach (Gettman et al, 2002b) . Moreover, the continued dynamism for workable new approaches sprung the inception of the first reported hybrid NOTES nephrectomy in a porcine model utilizing the da Vinci surgical system (Box et al., 2008) . Robotic technologies offer a potential improvement over the current flexible instruments and endoscopes. Other limitations include the indirect transmission of forces and space constraints for the operating surgeon (Table 2 ). In 2008, 30 urologic robotic NOTES procedures on 10 porcine models were performed using the current da Vinci robotic system . A 12 and an 8-mm port were placed through a single transumbilical incision to introduce the robotic camera along with a robotic arm using a single port (Uni-X (TM) P-navel Systems, Morganville, NJ). A flexible 12-mm cannula 20cm long (US Endoscopy, Mentor, Ohio, USA) served as a transvaginal port, through which the second robotic arm was docked. All interventions were conducted without complications or conversion. However, problems encountered included the inadequate length of transvaginal instruments, essentially prolonging surgical time. In order for widespread use of newer approaches, development of appropriate instruments should simultaneously occur. The Da Vinci® S robotic system using a LESS approach has also been applied to prostate surgery. A transvesical robotic radical prostatectomy was performed in a cadaver model (Figure. 3) . Articulated instruments and 3D vision facilitated the dissection of the prostate through the single-port. Moreover, architectural advances with the robotic system will allow accessibility to a wider range of surgeons interested in LESS and NOTES approaches. An example of robotic modifications helping the growth of LESS came www.intechopen.com with the advent of the novel robotic platform (VeSPA, Intuitive Surgical, California, USA) ( Figures. 4 & 5) . These curved cannulae and semi-rigid instruments have been designed to compensate for the limitations encountered with conventional LESS surgery. The VeSPA curved cannulae and semirigid instrument design allow the cannulae and instruments to be inserted in close proximity while allowing approximate triangulation intraabdominally. The VESPA platform was successfully applied in a porcine model without conversions or addition of ports (Haber et al., 2010b) . However, it is recognized that Robotic-LESS for the kidney is technically more challenging in humans compared to animal model. Therefore, further clinical research is required to confirm these early experimental results. The initial clinical experience with robotic single-port transumbilical surgery was reported in 2009 (Kaouk et al, 2009a) . A multichannel single port (R-port; Advanced Surgical Concepts, Dublin, Ireland) was inserted through a 2-cm umbilical incision into the abdomen. Three procedures were performed, including radical prostatectomy, dismembered pyeloplasty, and right sided radical nephrectomy. All procedures were completed without intraoperative complications. The radical prostatectomy was completed in 5 h, with 45 min required for the anastomosis. The pathology reported negative margins. The pyeloplasty was completed in 4.5 h, and the radical nephrectomy was completed in 2.5 h. R-LESS procedures were accomplished without additional ports or significant differences in peri-operative outcomes compared to standard robotic approaches. We recently reported our initial experience with single port robotic partial nephrectomy in two patients without conversions or complications (Kaouk et al. 2009b) . A multichannel port (Triport; Advanced Surgical Concepts, Bray, Co Wicklow, Ireland) was utilized. Pediatric 5mm robotic instruments were used. A 30° robotic lens placed in the upward configuration minimized clashing between the scope and instruments. A 2.8 cm left lower pole tumor and a 1.1 cm right lower pole tumor were excised without renal hilar clamping using the harmonic scalpel. EBL was 100 ml, operative time was 170 min, length of stay was 3.5 days, and visual analog pain scale at discharge was 1.0/10. Stein et al. reported robotic LESS using a gel port (Applied Medical, Rancho Santa Margarita, California, USA) as the access platform (Stein et al., 2010) . Four clinical procedures were performed, including two pyeloplasties, one radical nephrectomy, and one partial nephrectomy. The gel port system was used to allow for a larger working platform. The partial nephrectomy was completed in 180 min. The mass was excised without hilar clamping, using the harmonic scalpel and Hem-o-lok clips (Weck Closure Systems, Research Triangle Park, North Carolina, USA). A radical nephrectomy was performed for a 5-cm leftsided lower pole mass. The renal vein and artery were secured with an endoscopic stapler, and the remainder of the dissection was completed with hook cautery. The specimen was retrieved with an entrapment sac and removed via the umbilical incision extended to 4 cm. EBL was 250 ml, operative time was 200 min, and the hospital stay was 2 days. The Da Vinci system has several advantages over conventional laparoscopy allowing an increasing number of urologist adopt this method. Preliminary results of these minimal invasive approaches are encouraging in LESS and NOTES techniques. Further refinement in instrumentation, improved triangulation and development of robotic systems specific to LESS and NOTES may define the new horizons in single site surgery.
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Flexible robots
The development of robotic technologies has also flourished in endocopic surgeries. A flexible robotic catheter manipulator (Sensei, Hansen Medical, Mountain View, CA, USA) thought to allow enhanced ergonomics with improved efficiency over standard flexible ureteroscopy was developed by Sensei, Hansen medical. Initial experience in the porcine model showed promising outcomes. The novel robotic catheter system comprises the following components ( Figure. 6 & 7) , (a) surgeon console, including the LCD display and master input device, (b) steerable catheter system, (c) remote catheter manipulator, and (d) electronic rack. The master input device (MID) is a three-dimensional joystick the surgeon uses to remotely maneuver the catheter tip. The real-time image of ureteroscopy, fluoroscopy and representation in space of the catheter position is projected simultaneous on the screens. Furthermore, images from the CT scan or an ultrasound probe images display. The steerable catheter system contains an outer catheter sheath (14F/12F) and an inner catheter guide (12F/10F). The movement of the MID intuitively controls the tip of the catheter guide. The robotic arm, steerable catheter, is attached to the edge of the table. The catheter can be controlled either by fluoroscopy mode, direct vision from the ureteroscope or by a combination of both. In addition, a 3D reconstruction of the extremity the catheter is displayed on the screen, assisting in the identifying the location. Moreover, manoeuvrability is not diminished when the use of fiber laser 200 to 365 microns. The technical feasibility of the robotic catheter system was evaluated in retrograde renoscopy in the porcine model. Authors concluded that the robotic catheter system could easily manoeuvre the ureteroscope into 83 (98%) of the 85 calices tested in a reproducible manner. The ease and reproducibility of intra-renal navigation was rated at a mean of 10 of 10 on the VAS . Clinical investigation for flexible robotic system in ureteroscopy was performed in 18 patients who had renal calculi. Mean stone size was 11.9 mm. All procedures were done unilaterally and all patients had ureteral stents placed for 2 weeks. The robotic catheter system was introduced into the renal collecting system manually using fluoroscopic control along a guide wire. All intra-renal manoeuvres were performed completely by the surgeon from the robotic console. All procedures were technically successful, and all calculi were fragmented to the surgeon's satisfaction, without conversion to standard ureteroscopy. Mean operative time was 91 minutes, including a robot docking time of 7 minutes, and stone localization time of 9 minutes. The mean visual analog scale rating (from 1, worst, to 10, best) for ease of stone localization was 8.3, ease of maneuvering was 8.5, and ease of fragmentation was 9.2. Complete fragment clearance was achieved in 56% of patients at 2 months, and in 89% of patients at 3 months. One patient required secondary ureteroscopy for a residual stone (Desai et al, 2008c) Improvements in flexible instrumentation have brought a revolution with retrograde intrarenal surgery. Advancements in flexible ureteroscopes, laser lithotripsy, and ureteroscope accessories are contributors to the metamorphosis with robotics in endo-urology.
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Miniaturization has been the key advancement for the progression of robotics in endoscope. Further studies are needed to corroborate these early clinical results.
Robotic prostate biopsy
Incorporation of real-time radiographic imaging for biopsy or ablative treatment of urological cancer is currently in development. A robotic arm Vicky® (Endo-Control, Grenoble, France) and an ultra-sound probe (B-K Medical, Denmark), were utilized to perform tranrectal prostate biopsies. The software was modified to save up to 24 spatial coordinates and answer the constraints of transrectal ultrasound. Tests on phantom and human cadaver prostates demonstrated the feasibility of robotic transrectal ultrasound, with precision biopsies performed on a target tumor ranging from (0.1 to 0.9 mm) on the prostate and (0.2 to 0.9 mm) on the phantom (Figure. 8) . Initial results are encouraging with clinical trials forthcoming . Moreover, a robotic positioning system with a biplane ultrasound probe on a mobile horizontal platform was used to perform prostate biopsies in a phantom model. . The integrated software acquires ultrasound images for three-dimensional modeling, coordinates target planning and directs the robotic positioning system. A repeatable accuracy of <1 mm was obtained (Ho et al., 2009 ). This robotic prostate biopsy system can theoretically biopsy targets from MRI images after merging the ultrasound images, allowing treatment of positive areas found on biopsies. Presently, a fully automated robot system, the MrBot, has been developed for transperineal prostate access. (Patriciu et al., 2007) . It is mounted alongside the patient in the MR imager and is operated from the control room under image feedback. The robot presents 6 degrees of freedom: 5 for positioning and orienting the injector and 1 for setting the depth of needle insertion. The first driver was developed for fully automated low-dose (seed) brachytherapy. Compared with classic templates for needle guides, the robot enables additional freedom of motion for better targeting. As such, multiple needle insertions can be performed through the same skin entry point. In addition, angulations reduce the pubic arch interference, allowing better prostate access for sampling. The MrBot robot was constructed to be ubiquitous with medical imaging equipment such as ultrasound and MRI. An accuracy of 0.72 ± 0.36 mm was described for seed placement. Furthermore, multiple clinical interventions are possible with the MrBot system, such as biopsy, therapy injections, and radiofrequency ablations. Preclinical testing in cadaver and animal models has shown favorable results (Mozer et al., 2009 ).
Future trends in the design and application of surgical robots
Advances in robotic systems accompanied by trends toward miniature devices, microrobots and eventually nanorobots, are realistic near future advancements. Prototypes of the Microrobot cameras (15 mm /3 inches) were placed inside the abdomen of a canine model during laparoscopic prostatectomy and nephrectomy allowing for additional views (360-degree) of the surgical field The microrobot was mobile, controlled remotely to desired locations, further aiding the laparoscopic procedures (Joseph et al., 2008) . More recently, Lehman et al. showed the feasibility of LESS cholecystectomy in a porcine model, using a miniature robot platform (Lehman et al., 2011) . The robot platform incorporated a dexterous in-vivo robot and a remote surgeon interface console. In addition, www.intechopen.com multiple robots could be inserted through a single incision rather than the traditional use of multiple port sites. Capabilities such as tissue retraction, single incision surgery, supplementary visualization, or lighting can be delivered by these micro-robots. A well-known limitation of the current robotic platform is the lack of tactile feedback. However, the improved visualization and accuracy of robotic instrumentation may overcome this limitation. Furthermore, newer technologies with multiple compact robots, tracking tools, and tactile feedback apparatus may further expand the application of robotic surgery. 
Conclusion
Robotic applications in urology are effective and safe technologies. Surgical technique have evolved and indications have been expanded to more challenging scenarios. New technologies are constantly reshaping the urological sphere especially robotics. Further refinements in robotic systems along with a reduction in cost are key components for rapid assimilation amongst the urological community.
